Background/Aims: Aberrant activation of the Wnt/β-catenin signaling pathway plays a key role in the pathogenesis of multiple tumors including digestive cancers. Recent studies have reported that Dickkopf-related protein 2 (DKK2) is epigenetically inactivated in numerous types of cancers and that its gene products exhibit tumor-suppressive properties. However, the biological functions and underlying molecular mechanisms of DKK2 in colon carcinoma remains obscure. Methods: We examined the expression of DKK2 in colon tumor cell lines by RT-PCR and its promoter methylation status in colon tumor cell lines and primary tumors by methylation-specific PCR (MSP). Ectopic expression of DKK2 was measured by RT-PCR prior to the other experiments. To investigate the function of DKK2, we assayed colony formation and cell proliferation, utilized flow cytometric analyses of the cell cycle and acridine orange/ethidium bromide (AO/EB) fluorescence staining for apoptosis, and examined wound healing, transwell migration and tumor growth in vivo. Western blots were used to explore the mechanisms of DKK2 in epithelial-mesenchymal transition and canonical Wnt/β-catenin signaling. Results: We show here that downregulation or silencing of DKK2 was closely associated with the hypermethylation status of its promoter and that DKK2 expression could be restored by demethylation treatment. Methylation of the DKK2 promoter was detected in nearly all tumors and tumor-adjacent tissues, but not in normal colon tissues. Ectopic expression of DKK2 in colon cell lines HCT116 and HT-29 inhibited colony formation and cell viability by inducing cell cycle G0/G1 arrest and apoptosis, and growth of stable DKK2-infected HCT116 cells in nude mice was decreased compared to controls. Furthermore, DKK2 restrained cell migration through partial reversal of epithelial-to-mesenchymal transition and also by
Dickkopf-Related Protein 2 is Epigenetically Inactivated and Suppresses Colorectal Cancer Growth and Tumor Metastasis by Antagonizing Wnt/β-Catenin Signaling

Introduction
Colorectal cancer (CRC) is the leading cause of death among digestive tumors worldwide. According to the latest cancer statistics from the American Cancer Society, CRC accounted for 16% (134,490) of all cancer cases and 16% (49, 190) of cancer deaths in 2016 [1] . However, physical and biochemical technology for early diagnosis of colon cancer is still limited, underlining the importance of finding a reliable biomarker for the early detection of this disease. Although the specific mechanism of CRC tumorigenesis remains unclear, epigenetic inactivation of tumor suppressor genes by promoter methylation plays an important role in this cancer [2] . A previous study has demonstrated promoter methylation of tumor-related genes and expression of tumor suppressor genes (TSG) in gastrointestinal cancers and precancerous lesions, suggesting their involvement in the multistep progression of colorectal carcinogenesis. Thus, these epigenetically-modified genes could be potential biomarkers for colon cancer.
The Wnt signaling pathway is involved in tumorigenesis of various malignancies and consists of canonical Wnt/β-catenin signaling and non-canonical Wnt signaling independent of β-catenin [3] [4] [5] . Some of the Wnt signaling components are broadly involved in carcinogenesis and pathogenesis. For example, epigenetic and genetic alterations of β-catenin and adenomatous polyposis coli (APC) regulators in the Wnt signaling pathway have been demonstrated in many human tumors, including liver cancer [6] , gastric cancer [7, 8] and colon cancer [9, 10] . Therefore, aberrant activation of WNT signaling is a hallmark of carcinogenesis [11, 12] , and epigenetic modifications are an important mechanism for regulating this pathway [13] .
Researchers have found that aberrant DNA methylation is related to the genesis of early CRC lesions, indicating that epigenetic alterations are involved in the initiation of CRC [14] . Thus, epigenetic changes, especially the methylation of CpG islands in the promoters of tumor suppressor genes, may cause gene silencing and the onset of tumors [15, 16] .
The Dickkopf (DKK)-related protein family is composed of four secreted glycoproteins, DKK1 through DKK4. The DKK2 gene is located at 4q25, a commonly-deleted tumor suppressive locus in multiple tumors. Although epigenetic silencing of DKK2 by promoter methylation has been observed in several tumors [17, 18] , its biological functions and related molecular mechanisms in CRC have not been elucidated. In this study, we investigated DKK2 expression and promoter methylation status in CRC. We also analyzed the tumor-suppressive functions and mechanisms of DKK2 in CRC. Our findings suggest that DKK2 functions as a tumor suppressor and regulator of the Wnt/β-catenin pathway in CRC.
Materials and Methods
Cell lines and tumor samples
Human colon cancer cell lines (HT-29, HCT116, HCT15, LoVo, SW480, RKO and Caco2) were obtained from American type culture collection (Manassas, VA, USA). Cell lines were maintained in RPMI-1640 with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) at 37°C in a humidified atmosphere of 5% CO 2 as previously reported [19] .
All colon tissues were collected from surgical patients enrolled in the study as previously described [19] . Fresh specimens were obtained during surgery without any other therapeutic intervention from the Department of Gastrointestinal Surgery (the First Affiliated Hospital of Chongqing Medical University, Table 1 . List of primers used in this study. F, forward; R, reverse Bisulfite treatment and methylation analysis Bisulfite modification of DNA and methylation-specific PCR (MSP) were carried out according to our earlier reports [24] . Bisulfite-modified DNA was amplified with either promotermethylated (m) or unmethylated (u) primer sequences (methylationspecific primers are shown in Table  1 ). MSP for the DKK2 promoter was performed using AmpliTaq-Gold DNA Polymerase (Applied Biosystems), with the reaction conditions as follows: initial denaturation for 10 min at 95°C, then 40 cycles consisting of 95°C for 30 s, 60°C (methylated reactions) or 58°C (unmethylated reactions) for 30 s, 72°C for 30 s, and a final extension for 5 min at 72°C. Methylated and unmethylated human DNA were used as positive and negative controls, respectively.
DKK2 overexpression in HCT116 and HT-29 cells
For DKK2 ectopic expression, cDNA encoding DKK2 was subcloned 
Colony formation assay
For monolayer culture colony formation assays, stably-expressing DKK2 and empty vector control cells (HCT116 and HT-29) were plated in six-well plates and selected for 2 weeks in complete medium containing 2 µg/ml puromycin. Surviving colonies (≥50 cells/colony) were fixed with 4% paraformaldehyde, stained with Giemsa's solution and visible colonies were counted. The experiments were repeated three times.
Cell proliferation assay
Cell proliferation was assessed by MTS assay. Stable DKK2-expressing and empty vector cells (HCT116 and HT-29) were seeded in 96-well plates (3000 cells/well) with 100 µL of complete culture medium. Cells were incubated for 24, 48 or 72 h, followed by the addition of 100 µl/well of medium containing 20 µl MTS reagent and subsequent incubation at 37°C for 2 h. Absorbance was measured at 490 nm using a microplate reader (Multiskan MK3; Thermo Fisher Scientific). Data were obtained from three independent cultures and each experiment was repeated three times.
Flow cytometry analysis of cell cycle and apoptosis
For cell cycle assays, HCT116 and HT-29 cells were cultured in six-well plates at a density of 2×10 5 cells/ well and grown overnight. Cultures were then transiently infected with LV-DKK2 or LV-control according to the manufacturer's instructions. After 48 h, cells were collected, digested and centrifuged at 1000 rpm for 5 min. Cells were washed twice with phosphate buffer saline (PBS), fixed in ice-cold 70% ethanol overnight and treated with 50 μg/l propidium iodide (PI; BD Pharmingen, San Jose, CA, USA) for 30 min at 4℃ in the dark. The cells were sorted using a FACSCalibur machine (BD Biosciences, Franklin Lakes, NJ, USA) and data were analyzed by ModFit 3.0 software (Verity Software House, Topsham, ME, USA).
Apoptosis was measured using annexin V-fluorescein isothiocyanate (FITC; BD Pharmingen) and PI according to the manufacturer's protocol. Data were analyzed using CellQuest™ Pro (BD Biosciences). Acridine orange/ethidium bromide (AO/EB) fluorescence staining was also used to examine cell apoptosis as described [19] . After infection for 48 h, cells were washed three times with PBS and visualized immediately under a fluorescence microscope.
Wound healing and transwell assays
Stably-infected cells were plated in six-well plates (5×10 5 cells/well) until 90% confluent. Cell layers were scratched using sterile P-20 pipette tips, then washed twice with PBS to carefully remove cell debris and incubated in serum-free media. The cell-free wound area was photographed every 12 hours at 100× magnification. The experiments were performed in triplicate.
Transwell chambers (8-μm pore size; Corning, Corning, NY, USA) were also used to assess cell migration ability as described previously [25] . Cells were collected and washed twice in serum-free medium, then added to the upper chamber (5×10 4 cells/chamber), with 700 μl migration induction medium containing 10% FBS in the lower chamber. After incubation for 48 h, the lower side of the inserts was fixed with In vivo tumorigenicity HCT116 cells stably infected with LV-DKK2 or empty LV-control (5×10 6 cells in 0.2 ml serum-free medium) were injected subcutaneously into female BALB/c nude mice (4 weeks old, five mice/group). Tumor volume (mm 3 ) was calculated using the following equation: volume=0.5×length×width 2 . When the length of the tumor reached 1 cm, the mice were euthanatized and xenograft tumors were removed. The tumors were immediately weighed, then fixed, dehydrated and embedded in paraffin for immunohistochemistry and hematoxylin/eosin (HE) staining. The animal experiment was authorized by the Committee on Ethical Use of Animals of Chongqing Medical University.
Western blot analysis
Cells were collected 48 h post-infection for protein extraction, using protein extraction reagent (Thermo Scientific, Rockford, IL, USA) containing a phosphatase inhibitor cocktail (Sigma-Aldrich) and the protease inhibitor phenylmethanesulfonyl fluoride. Proteins (40 μg/lane of total extract) were subjected to western blotting as previously described [25] . The primary antibodies used were as follows: DKK2 (1:1000, ab38594; Abcam, Cambridge, UK), β-catenin (1:1000, #2677; Cell Signaling, Danvers, MA, USA), active-β-catenin (1:1000, #4270; Cell Signaling), phosphor-Gsk-3β (1:1000, #9322; Cell Signaling), cyclinD1 (1:1000, #2261; Epitomics, Burlingame, CA, USA), c-Myc (1:1000, #1472-1; Epitomics), p21 (1:1000, sc-126; Santa Cruz Biotechnology, Santa Cruz, CA, USA), p27 (1:1000, sc-393380; Santa Cruz), E-Cadherin ; Cell Signaling) and β-actin (1:1000, LK-ab008-100; Liankebio, China) as a control. Protein blots were analyzed using an enhanced chemiluminescence kit (ECL; Amersham Pharmacia Biotech, Piscataway, NJ, USA) and visualized with a Las-4000 Imaging System (Medical Systems, Fujifilm Global, Tokyo, Japan).
Immunohistochemistry staining
Immunohistochemistry was performed on paraffin sections of transplanted tumor tissues from nude mice, using anti-DKK2 (1:200, ab38594; Abcam) and anti-Ki67 (1:200, ab15580; Abcam) antibodies. In brief, the tissue samples were sectioned at 4 μm and then dewaxed, rinsed in absolute xylene and rehydrated through graded alcohol. Antigen retrieval was performed as previously described [25] . The section samples were incubated in 3% hydrogen peroxide to block endogenous peroxidase activity, washed three times with PBS and then blocked with 5% FBS-PBS solution at room temperature for 15 min. The sections were incubated with the primary antibody at 4°C overnight. The next day, the sections were incubated with secondary antibody (1:1000 dilution) for 60 min at room temperature, followed by color development with diaminobenzidine and counterstaining with hematoxylin (HE). Images were captured under a microscope at 400× magnification.
Statistical analysis SPSS 16.0 statistical software (SPSS Inc. Chicago, IL, USA) was employed for statistical analyses. All data were expressed as means ± standard deviation (SD). Data were analyzed using Student's t-test and the chi-square test as appropriate. Differences were considered statistically significant when p <0.05.
Results
DKK2 is frequently downregulated in CRC tumor tissues and cell lines
To examine the relative expression levels of DKK2 in CRC specimens, analysis of DKK2 mRNA expression was performed using an online cancer microarray database. Data from Oncomine (Compendia Bioscience, Ann Arbor, MI) and TCGA colorectal statistics (https:// we used RT-PCR to examine mRNA expression of DDK2 in CRC cell lines and normal colon tissues. DKK2 was absent or downregulated in nearly all of the CRC cell lines, but was strongly expressed in normal colon tissue (Fig. 1C) .
DKK2 downregulation is mediated by promoter methylation in colon cancer
Abnormal promoter methylation is an important mechanism responsible for the silencing of many TSGs in carcinogenesis [26] . Our initial report demonstrated that typical CpG islands were present in the promoter region of DKK2 using CpG island analysis software (CpGPlot/CpGReport/Isochore, provided by the European EBI) [27] . We used MSP to analyze DKK2 promoter methylation status in seven colon tumor cell lines. Methylation of the DKK2 promoter was observed in all of these cell lines, which was consistent with the low expression or silencing of DKK2 (Fig. 1C) . To determine if DKK2 expression was regulated by promoter methylation, we treated three colon cancer cell lines (HCT116, HT-29 and SW480) with demethylation drugs Aza and TSA and then performed RT-PCR and MSP analysis. Results showed that pharmaceutical demethylation restored DKK2 expression in all three cell lines, along with an increase in unmethylated promoter alleles in HT-29 cell lines (Fig. 1D) . Thus, silencing of DDK2 expression in CRC was at least partially caused by methylation of its promoter. Data taken from an online database (http://methhc.mbc.nctu. edu.tw/php /index.php) showed that downregulation of DKK2 expression was inversely correlated with its promoter CpG methylation status (for online suppl. material, see www. karger.com/doi/10.1159/000471861). We also investigated DKK2 promoter methylation in paired colon tumor tissues. We observed that hypermethylation of the DKK2 promoter commonly occurred in nearly all primary colon tumors, and also found significantly lower methylation in paired tumor-adjacent tissues, but not in normal colon tissues (0/10; Fig.  2A, 2B ). However, there was no correlation between DKK2 promoter methylation and clinicopathological characteristics (data not shown).
DKK2 suppresses tumor cell growth and viability in colorectal cancer cell lines
To ascertain whether DKK2 is a functional TSG in CRC, we used MTS and colony formation assays to examine cell viability and proliferation after stable ectopic expression of DDK2 and empty vector viruses in HCT116 and HT-29 cell lines. Ectopic expression of DKK2 in HCT116 and HT-29 cell lines was confirmed by RT-PCR (Fig. 3A) . MTS cell viability assays showed that ectopic expression of DKK2 in HCT116 and HT-29 cell lines resulted in a significant decrease in cell viability at 24, 48 and 72 h post-infection (p <0.05, Fig. 3B ). Furthermore, in colony formation assays we found that the colonies formed after DKK2 expression in HCT116 and HT-29 cell lines were significantly fewer and smaller than those formed after infection with the empty vector control (reduced to 40%-80% of empty control, p <0.001, Fig. 3C,  3D ), indicating that DKK2 suppressed the proliferation and tumorigenicity of CRC cell lines. In addition, qRT-PCR showed that mRNA expression of cell cycle-related CCND1 decreased while p21 expression increased (Fig. 3E) . Western blots further verified that overexpression of DKK2 decreased the expression of CCND1 and upregulated p21 and p27 proteins (Fig. 3F ).
DKK2 causes cell cycle arrest in G0/G1 phase and induces apoptosis
Flow cytometric analyses of cell cycle and apoptosis were performed to confirm the mechanisms underlying DKK2 suppression of cell growth. After 48 h of infection, DKK2 significantly increased the percentage of HCT116 and HT-29 cells in G0-G1 phase by 10%-20% compared to controls (p <0.001, Fig. 4 ). These results suggested that DKK2 inhibition of cell proliferation was likely mediated by inducing cell cycle arrest at G0/G1. AO/EB staining was performed to detect apoptotic changes and showed an increase in the number of cell nuclei showing concentrated orange fluorescence in cells infected with DKK2, indicating late apoptotic cells (p <0.01, Fig. 5A , 5B). Furthermore, we also evaluated the distribution of apoptosis induced by DKK2 using double staining with Annexin Caspases involved in the proteolytic cascade need to work together to execute apoptosis [28] . Western blots showed that DKK2 significantly promoted the generation of cleaved-caspase 3 and cleaved-caspase 7 in both cell lines compared with the vector controls (Fig. 5E) . Overall, these analyses indicated that the inhibition of cell proliferation by DKK2 was most likely mediated by inducing G0/G1 cell cycle arrest and apoptosis.
DKK2 inhibits migration of colon tumor cells and epithelial-mesenchymal transition (EMT)
To investigate whether ectopic expression of DKK2 altered cell migration, we first tested the effects of DKK2 on CRC cell migration through monolayer wound-healing scratch assays. Results showed that compared with cells infected with the empty control vector, ectopic expression of DKK2 in cell lines delayed the closure of wound gaps as observed at 12 h intervals (p <0.05, Fig. 6A ). Furthermore, to quantitatively assess cell migration, transwell chamber assays showed that the number of migrating cells with ectopic expression of DKK2 was obviously reduced compared with control cells (p <0.01, Fig. 6B ). These results suggested that DKK2 indeed possesses the ability to inhibit migration of colon cancer cells.
In CRC, the EMT program affects a series of malignant phenotypes related to metastasis, including the generation of colon stem cells (CSCs), circulating tumor cells, tumor budding and drug resistance [29] . In the present study, qRT-PCR demonstrated that the expression of epithelial marker E-cadherin was upregulated by DKK2 overexpression, while vimentin, N-cadherin and twist were repressed (p <0.001, Fig. 6C ). In addition, western blot analysis indicated that E-cadherin was increased while vimentin and N-cadherin were decreased in DKK2-overexpressing cell lines (Fig. 6D ), indicating that DKK2 was a negative regulator of EMT. Since EMT has been implicated as a key factor regulating the generation of CSCs [29, 30] , we further examined the expression of stem cell markers in DKK2-infected colon cancer cells. DKK2 downregulated stem cell markers in HCT116 and HT-29 cell lines (Fig. 6E, 6F) , and thus may play a role in reversing the stem cell-like phenotype of tumor cells.
DKK2 inhibits xenograft tumor growth in nude mice
Given its anti-proliferative activity and ability to inhibit EMT in vitro, we further explored whether DKK2 could alter growth and EMT of CRC cells in nude mice in vivo. Tumors were excised from nude mice 23 days after injection, as shown in Figure 7 . Tumor size and mean tumor weight was significantly lower in test mice compared with control (Fig. 7A,  7B, 7C) . Immunohistochemistry was performed to analyze the expression of DKK2 protein, as well as cell proliferation-associated protein Ki-67 expression (Fig. 7D) . Ki-67 expression was significantly reduced in tumors expressing DKK2 compared with control (Fig. 7D) . In addition, the proliferation of DKK2-infected xenografts was suppressed due to escalating apoptosis, as the levels of cleaved poly ADP-ribose polymerase (PARP) and cleaved caspase-3 were significantly higher than the control group (Fig. 7E, 7F ), indicating that DKK2 acted as a TSG in CRC tumorigenesis in vivo. Meanwhile, western blot analysis showed that E-cadherin was increased, while vimentin and N-cadherin expression decreased in DKK2-infected xenografts ( Figure 7E, 7F) , suggesting that DKK2 was a negative regulator of EMT in vivo.
DKK2 antagonizes the canonical Wnt/β-catenin signaling pathway
We further analyzed whether the mechanism underlying the tumor-suppressive function of DDK2 was related to Wnt signaling, since Wnt/β-catenin signaling plays an important role in regulating proliferation and EMT in cancer [31, 32] . Western blots were performed to determine if DKK2 neutralized Wnt/β-catenin signaling. We found that in HCT116 and HT-29 cell lines, DKK2 expression significantly inhibited the expression of active β-catenin without change in total β-catenin (Fig. 8) . β-catenin plays a key role in activating the transcription factor T-cell factor/lymphocyte enhancer factor (TCF/LEF) [33] . However, in our study, the were also downregulated by DDK2 expression (Fig. 8) . In summary, these findings suggested that DKK2 may regulate CRC progression, at least partly, by antagonizing Wnt/β-catenin signaling through reduction of β-catenin/ TCF-mediated transcriptional activity. 
Discussion
Previous studies identified DKK2 as a functional tumor suppressor in multiple cancers which is silenced by promoter methylation [17, 18] . The direct relationship between the function of DKK2 and its related mechanisms in CRC remains unclear. In this study, we found that DKK2 was expressed in normal colon tissues, but was frequently absent or downregulated in colon cancer cell lines. The reduced expression was associated with promoter methylation, and demethylation agents were able to restore DKK2 expression in epigenetically-silenced colon cancer cells. Other studies have confirmed that hypermethylation of DKK2 is a frequent event in CRC [34, 35] . Our results suggest that DKK2 expression is epigenetically inactivated through promoter-specific hypermethylation in colon cancer. Data from multiple online databases have also shown that expression of DKK2 is inversely correlated with its promoter CpG methylation (http://methhc.mbc.nctu.edu.tw). In addition, we found that expression of DKK2 in most colon cancer tissues is downregulated by analyzing the online Skrzypczak colorectal database, and further observed reduced DKK2 gene copy numbers in the Kurashina Colon and TCGA Colorectal datasets. A DNA copy number variant is defined as a DNA segment that is >1 kb in size and is present at a variable copy number in comparison with a reference genome. Copy number variants can impact the organization of chromatin and gene expression. Gene copy number was also decreased in colon adenocarcinoma and MCC. Moreover, in a study of DKK2 protein expression, Tadateru found that DKK2 was reduced in a certain subset of cancer tissues compared to normal colon tissues, with weak or negative staining in 27/60 (45.0%) of CRC tissue sections. Taken together, the above results indicate that DKK2 is downregulated in CRC.
We next investigated the functions of DKK2 in two colon cancer cell lines. It was reported that the members of the DKK family were associated with cancer cell proliferation and other biological functions, including apoptosis and migration/ invasion in multiple tumors [17, 18] . Therefore, we focused primarily on these anti-tumor activities. We found that DKK2 infection suppressed cell proliferation in vitro and increased the percentage of cells in G0/ G1 phase. In vivo, the diminution of tumor growth by DKK2 overexpression was also verified by xenograft tumor formation in nude mice. In addition, the number of apoptotic cells was increased after DKK2 infection, accompanied by changes in apoptotic morphology. It has been reported that ectopic-expression of DKK2 restrained metastasis in human ovarian carcinoma [17] . We found that migration of HCT116 and HT-29 cells was slightly restrained after DKK2 infection, consistent with these previous reports. These results together strongly suggest that DKK2 functions as a tumor suppressor in CRC cells. A number of reports have suggested that Wnt/β-catenin signaling is frequently affected in a broad series of human malignancies. However, most of these studies described strong activation of the Wnt/β-catenin pathway in colon cancer cell lines, resulting from gainof-function mutations in β-catenin (HCT116, SW48, Colo205, LS174T) or loss-of-function mutations in the destruction complex component APC (SW480, HT29, DLD1, LoVo, SW620, Caco2, Colo205, SW1116, Colo320) [36, 37] . Increasing evidence has confirmed that these tumor-causative mutations lead to defective stabilization of β-catenin and loss of nuclear β-catenin/TCF-dependent translocation, and further activate downstream target genes related to cell proliferation and transformation [38] . DKK2, as a negative regulator of the WNT signaling pathway, can suppress WNT signaling in ovarian and renal carcinoma [17, 18] . Whether or not DKK2 could inhibit the WNT signaling pathway in CRC was largely unknown. We found that overexpressing DKK2 led to an obvious downregulation of Wnt/β-catenin signaling in both HCT116 and HT-29 cell lines. Moreover, to obtain more detailed information about DKK2 mechanisms, we found that pertinent markers of Wnt/β-catenin downstream targeted genes, including p-GSK3β, c-Myc, CCND1 and various MMPs were also significantly downregulated. Thus, DKK2 antagonized Wnt/β-catenin signaling. Whether or not DKK2 could influence mutations of β-catenin and APC need further study.
EMT confers cells with stem-like properties, containing invasiveness with a gain of mesenchymal characteristics and a loss of epithelial characteristics [31] . Two major factors regulating tumor metastasis are tumor cell invasion and degradation of extracellular matrix by specialized proteolytic enzymes. MMPs are an important part of these proteolytic enzymes [39] . They are highly expressed in multiple malignancies, including breast cancer [40] , ovarian cancer [41] , lung cancer [42] and colon cancer [43] . In addition, it has been reported that blockade of the expression and activity of MMPs could be the major cause of reduced motility and metastasis of cancer cells [44] . Our research indicated that ectopicexpression of DKK2 downregulated the expression of MMP7, MMP11 and MMP14, suggesting that DKK2 can suppress tumor metastasis by modulating cancer tissue-remodeling enzymes. We also found that suppression of CD44 is involved in this process. CD44 is a receptor for hyaluronic acid and influences many characteristics of cancer cells, including stemness [45] . This suggests that DKK2 could possibly act as a suppressor of colon cancer stemness and thus may play a role in the initiation of the disease, which should be further examined. Cumulatively, the aforementioned results provide details on the prospective role of DKK2 in the regulation of Wnt/β-catenin signaling, a mechanism that may be responsible for colorectal carcinogenesis.
Recent literature has reported that some Wnt proteins (such as Wnt4, Wnt5A and Wnt11) were not directly involved in β-catenin/TCF-mediated transcriptional regulation, but rather induced Ca 2+ flux to block downstream signaling by inhibiting TCF-mediated transcription, and thus were actually involved in cancer metastasis [46] . Other DKK family members such as DKK3 can also mediate non-canonical c-Jun N-terminal kinase (JNK) signaling, which regulates apoptotic cell death and has been well-documented [27] . In this study, we found no significant evidence in our western blot results for Wnt/β-catenin crosstalk with either Notch or the JNK pathway (data not shown). Although we did not examine nuclear factor-κB and other noncanonical pathways, our research nonetheless suggests that DKK2 may suppress colon cancer progression primarily through the canonical Wnt pathway.
In summary, our research has shown that DKK2 expression was epigenetically silenced in CRC, which affected relevant mechanisms governing proliferation, apoptosis and metastasis. These results suggest that DKK2 functions as a tumor suppressor by antagonizing the Wnt/ β-catenin signaling pathway in colorectal tumorigenesis and progression. Thus we provide a rationale for using DDK2 along with other TSGs as candidate biomarkers for the early detection and prognosis of colon cancer.
